CytoMed Therapeutics Limited (NASDAQ:GDTC) Stock Short Interest Report for September

CytoMed Therapeutics Limited (NASDAQ:GDTC) saw a significant growth in short interest in September. As of September 30th, there was short interest totaling 17,102 shares, a growth of 372.4% from the September 15th total of 3,620 shares. Based on an average daily volume of 15,986 shares, the short-interest ratio is presently 1.1 days. Approximately 0.1% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

Several research firms have recently commented on GDTC. Weiss Ratings reiterated a “sell (e+)” rating on shares of CytoMed Therapeutics in a research report on Friday, October 2nd. Fundamental Research set a $4.16 price objective on CytoMed Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, September 15th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $4.16.

CytoMed Therapeutics Stock Performance

Shares of NASDAQ GDTC traded down $0.05 during trading on Friday, reaching $0.89. The company had a trading volume of 11,819 shares, compared to its average volume of 19,302. CytoMed Therapeutics has a twelve month low of $0.68 and a twelve month high of $3.68. The stock has a 50-day moving average price of $0.90 and a two-hundred day moving average price of $0.98.

CytoMed Therapeutics (NASDAQ:GDTC) last issued its quarterly earnings data on Wednesday, September 30th. The company reported ($0.06) earnings per share (EPS) for the quarter. The firm had revenue of $0.06 million during the quarter.

CytoMed Therapeutics Company Profile

CytoMed Therapeutics Limited (NASDAQ: GDTC) is a Singapore-based biotechnology company focused on developing cell-based immunotherapies for cancer. The company’s research programs are designed to use immune cells to recognize and attack cancer cells, with an emphasis on potentially scalable, off-the-shelf treatments.

CytoMed’s technology platform includes the development of allogeneic cell therapies derived from healthy donors, including therapies based on gamma-delta T cells and other immune-cell types.